Consensus Estimates
Metric
Q4 FY2025 Estimate
Q4 FY2024 Actual
YoY Change
Revenue
~$40–50M
~$59.5M
~-24%
EPS (Non-GAAP)
—
—
Watching for cash burn
Active Clinical Programs Supported
Watching for stabilization
—
Key leading indicator
Analyst consensus: Strong Buy (9 analysts). Average price target: $12.83 vs. current price of $8.21.
Key Metrics to Watch
1. Biopharma Logistics Revenue and Active Program Count
Cryoport’s core value is the number of CGT clinical programs using its cold chain services. When programs advance from Phase 1 to Phase 2 to commercial launch, revenue per program scales dramatically. When programs fail or are discontinued, that revenue disappears entirely. The active program count — and specifically how many are in late-stage trials or commercial phase — is the most important leading indicator for future revenue. Any stabilization or growth in this metric would be a meaningful positive signal after a painful period of CGT industry setbacks.
2. FY2025 Full-Year Revenue vs. $177M Estimate
The FY2025 annual revenue estimate of $177.12M implies a sharp 22% decline from FY2024’s $228.39M — but the TTM figure through September 2025 was $243.8M, creating a discrepancy. Either the Q4 expectation is extremely low (perhaps reflecting a known contract loss or program discontinuation), or the annual estimate is stale. Clarifying this gap is essential. If actual FY2025 revenue comes in well above $177M, it would represent a material positive surprise relative to the depressed baseline.
3. Impairment Charges
The 2021 acquisition of CRYOPDP — a European temperature-controlled logistics network — was done at a high price and has been a significant drag on the company’s financials, contributing to large impairment charges (FY2024 GAAP net loss was -$114.76M primarily due to write-downs). Last year, the company sold CRYOPDP to DHL Group.
4. Free Cash Flow and Liquidity
Cryoport burned $33.58M in free cash flow in FY2024, and the GAAP losses have been significant. Investors are acutely focused on runway — how much cash does the company have, and at what burn rate? Any guidance that suggests the company needs to raise capital would be a severe negative. A credible path toward FCF breakeven in FY2026 would be one of the most constructive things management could say tonight.
5. FY2026 Outlook and CGT Pipeline Commentary
Management’s forward guidance and tone on the CGT market pipeline will define how the stock trades over the next quarter. Cryoport is fundamentally a bet on the long-term growth of cell and gene therapy — an enormous market that has been slower to commercialize than early investors hoped. Any specifics on upcoming commercial product launches that will use Cryoport’s infrastructure, new client wins, or regulatory approvals expected in 2026 would be the clearest articulation of why the stock still has upside from here.
Scenario Analysis
Scenario
Revenue
Cash Burn
CGT Programs
Stock Reaction
**Bull**
>$55M Q4; FY above $210M
Narrowing toward breakeven
Active count stabilizes/grows
+15% to +25%
**Base**
~$45–52M Q4; FY ~$185–200M
Modest improvement
Flat program count
-5% to +10%
**Bear**
<$42M Q4; FY below $180M
Worsening or capital raise signal
Program count declining
-18% to -28%
Bull case: Q4 revenue comes in above $55M, the full-year significantly beats the depressed $177M estimate, and management points to a specific pipeline of commercial CGT launches in 2026 that will drive meaningful revenue recovery. Free cash flow improves materially. The stock, deeply beaten down, begins recovering toward the $10–12 range.
Base case: Revenue is roughly in line with estimates, and management offers cautiously optimistic commentary on the CGT pipeline without specific catalysts. The stock stabilizes near current levels — a relief given that any sign of existential risk would push it lower.
Bear case: Revenue misses badly, the TTM-versus-annual estimate discrepancy resolves unfavorably (Q4 was awful), and management signals that a capital raise may be necessary. The stock breaks below the $7 analyst low-end target, testing levels where the CGT infrastructure thesis is effectively priced for failure.
Context: Recent Trends
Cryoport’s story is inextricably linked to the commercial trajectory of the cell and gene therapy industry. In the early 2020s, CGT was the hottest space in biopharma — dozens of programs in late-stage trials, multiple commercial approvals anticipated, and Cryoport positioned as the essential cold chain infrastructure play. Investors bid the stock to $70+ on the thesis that every CGT commercial launch would generate durable, high-margin logistics revenue for Cryoport.
What happened instead: clinical trial failure rates in CGT remained stubbornly high, manufacturing challenges delayed commercial rollouts, and several high-profile programs (particularly in gene editing) failed to reach the market or were discontinued entirely. Simultaneously, Cryoport’s CRYOPDP acquisition — meant to build a global European logistics network — proved more expensive to integrate than anticipated and generated large write-downs. The stock’s collapse from $70+ to $8 reflects both the industry-wide CGT reset and company-specific execution concerns.
The long-term bull thesis isn’t dead. CGT remains a transformational medical technology, and Cryoport genuinely is the leading specialized cold chain provider for these therapies. As the industry matures and more products reach commercial approval — CAR-T therapies, gene editing treatments, and next-generation cell therapies — Cryoport’s infrastructure becomes more valuable. The question is whether the company can survive the gap period with enough cash and operational discipline to be there when the wave arrives. Tonight’s results will either reinforce that the company is managing the transition reasonably well, or deepen concerns that the financial pressure is becoming acute.
Earnings call begins after market close. Follow AlphaStreet for live transcript coverage and post-earnings results analysis.
Source: StockAnalysis, AlphaStreet Earnings Calendar. Estimates as of March 3, 2026. Consensus figures are approximate and subject to revision.
